

Silvia Mihaela Ilie, MD PhD

Department of Medical Oncology
Cancer Biology Transfer Platform
Georges Francois Leclerc Cancer Center
1 rue du professeur Marion 21000 Dijon,
France

+33 380 73 75 28

Silie@cgfl.fr

silviailie@gmail.com



Personal Details

Date of birth: 8 June 1973

Nationality: Romanian

Marital status: married, two children

Education

Medical:

- MD in General Medicine, University of Medicine and Pharmacy Timisoara, Faculty of Medicine, Romania, October 1998. Thesis title: *Cancer epidemiology in Romania after 1998*

Postgraduate:

- **Certificate of Competence in Breast Cancer:** European School of Oncology, June 2024
- **PhD in Medical Oncology,** University of Medicine and Pharmacy Bucharest, October 2012 to October 2017, Research project: *Tumour immunohistochemistry biomarkers to be proposed for a prognostic signature in non-metastatic, triple-negative breast cancer;* director Professor Anghel R
- **Doctoral Research Training in Medical Sciences,** Université Libre de Bruxelles, Belgium, October 2012 to October 2013, director Professor Awada A
- **Medical Oncology Specialty,** University of Medicine and Pharmacy Bucharest, Romania, March 2007
- **University Diploma in Biostatistics,** University of Health and Law Lille 2, France, October 2014 to June 2015, Prof Duhamel A
- **University Diploma of Clinical Oncology,** University Paris-Sud XI, Institute Gustave Roussy Villejuif, France, October 2011 to June 2012, Professor Fizazi K
- **University Diploma in Palliative Care,** University of Medicine and Pharmacy Bucharest, October 2008 to May 2010, Associate Professor Mosoiu D

Medical Training

Junior Specialist : Institute Gustave Roussy, France 1 May 2010 to 18 May 2012.

Residency: Medical Oncology, University of Medicine and Pharmacy Carol Davila Bucharest, Institute of Oncology. Prof. Alexandru Trestioreanu. Bucharest, Romania: February 2001 to March 2007

Internship: General Medicine, Regional Hospital Costesti City, District Arges, Romania: January 1999 to March 2000

Licenses & Certifications

- Medical Oncologist Certification in Belgium: August 2012
- Medical Oncologist Certification in France: June 2011
- Board-Certified Medical Oncologist: May 2007
- General Practitioner Certification: November 2000

Professional Affiliations

- French Order of Physicians
- Belgian Order of Physicians
- Romanian Order of Physicians
- Romanian Society of Oncology and Radiotherapy
- European Society of Medical Oncology
- European School of Oncology: Graduate

Professional Appointments

Senior Medical Oncologist: Georges Francois Leclerc Cancer Center, Dijon, France. 1th January 2017 to present

- Assessing and managing in- and outpatients with breast cancers.
- Multidisciplinary team attendance in breast cancer tumour board
- Including and reviewing patients on clinical trials, according to protocol and clinical need, as principal or co-investigator
- Developing and conducting laboratory and clinical research projects
- Deriving and implementing new guidelines for daily practice
- Supervising oncology residents' activity
- Bedside teaching
- Teaching sessions for medical students and senior residents in Medical Oncology

Senior Medical Oncologist: Institute of Oncology Alexandru Trestioreanu Bucharest, Romania. 10 December 2015 to 28 February 2017.

- Assessing and managing in- and outpatients with breast cancer
- Developing and conducting laboratory and clinical research projects
- Teaching sessions for senior residents in Medical Oncology

Senior Medical Oncologist: University Hospital C. Huriez Lille, France. 9 December 2013 to 9 December 2015.

- Assessing and managing in- and outpatients with gastrointestinal, hepato-pancreatic, breast and gynaecologic cancers
- Multidisciplinary team attendance: gastrointestinal, hepatopancreatic, breast and gynaecologic cancers
- Including and reviewing patients on clinical trials, according to protocol and clinical need, as principal or co-investigator
- Developing and conducting laboratory and clinical research projects
- Deriving and implementing new guidelines for daily practice
- Supervising oncology residents' activity
- Bedside teaching; organizing and participating in weekly oncology teaching sessions for students, residents, and nurses

Senior Medical Oncologist: Institute Jules Bordet Brussels, Belgium. 1 August 2012 to 15 November 2013.

- Assessing and managing the care of in- and outpatients with breast, gynaecologic and melanoma cancers
- Multidisciplinary team attendances for breast cancers, gynaecologic cancers, solid tumours in general and head and neck cancers
- Including and reviewing patients on clinical trials as co-investigator, according to protocol and clinical need
- Developing and conducting clinical research projects
- Supervising oncology residents' activity
- Bedside teaching; organizing and participating in weekly oncology teaching sessions for residents

Associate Medical Oncologist: Institute Gustave Roussy, France. 1 May 2010 to 18 May 2012.

- Assessing and managing in- and outpatients with head and neck, and lung cancers
- Multidisciplinary team attendances for head, neck and lung cancers and early-phase trials
- Developing clinical research projects
- Deriving and implementing new guidelines for daily practice
- Supervising junior residents' activity
- Bedside teaching; weekly oncology teaching sessions for residents and informal courses regarding supportive treatment in cancer care

Senior Medical Oncologist and Head of Medical Oncology Department: Regional Hospital Campulung Muscel, Arges District, Romania. 15 May 2007 to 30 April 2010.

- Assessing and managing in- and outpatients with a wide variety of solid tumours
- Leading oncological team
- Representing colleagues on the Departmental Health Committee
- Bedside teaching; formal and informal courses for nurses and GP residents

Research Experience

Clinical Trials(the last 5 years)

LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- early-stage breast cancer at very low risk of metastasis since 2024

CAMBRIA-2: Adjuvant Endocrine-based Therapy Study of Camizestran in ER+/HER2- Early Breast Cancer: since 2025

Neo-CheckRay Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: since 2022

HER2CLIMB-02, Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer: since 2021

PATINA, Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer: since 2021

PALATINE, Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients: since 2021

IMpassion030, Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer: since 2020

KEYNOTE-756, Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer: since 2020

StrateGlio, Intensification With Temozolomide in Adults With a Glioblastoma since 2020

NATALEE, Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer: since 2019

IMpassion132, Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer: since 2019

PANIRINOX Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients: since 2019

STELLAR, Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients: since 2019

Principal investigator

ALTERNATIVE: Cureety digital telemonitoring in the treatment of metastatic triple-negative breast cancer phase III: depuis 2024

EMERALD : Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: phase III : 2019-2022

RIGOLETTO Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma since 2021

PRODIGE 35 (PANOPTIMOX), First-line Metastatic Pancreatic Cancer: FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem: in 2015

PRODIGE 37(FIRGEMAX), First Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine: in 2015

Personal Research Protocols

Predictive and prognostic role of Human Endogenous Retrovirus K in operable breast cancer: laboratory

Biomarkers of Cancer Related Fibroblasts in Liver Metastasis of Colorectal Cancer : laboratory

Immunohistochemical prognostic score in residual triple-negative breast cancer after neoadjuvant chemotherapy: translational

Immunohistochemical prognostic signature in early triple-negative breast cancer: translational

Lomustine added to up front Temodal at progression in MGMT methylated GBM: interventional

Laboratory Internships

Laboratory of Human Molecular Biology Laboratory, Oscar Lambret Cancer Center, Lille Cedex, France. **Molecular analysis of BRCA1 and BRCA2 mutations by the Sanger sequencing method**, January 2014 to March 2014

Institute of Biology, Louis Pasteur, CNRS UMR8161, Lille Cedex France. **Western blot and immunohistochemistry HIC1 analysis in breast cancer cell cultures**, May 2014 to June 2014

Publications

Articles or Abstracts (as first/last author the last 5 years)

•Overall expression of human endogenous retroviruses in early breast cancer and their correlation with immunogenicity Lecuelle J, Truntzer C, Ladoire S, Ilie SM Annals of Oncology 35 (2024) S329

•Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy. Ilie SM et al. Front. Oncol., 13(2023)
doi.org/10.3389/fonc.2023.1309890

•Pathologic and immunohistochemical prognostic score in residual triple-negative breast cancer after neoadjuvant chemotherapy. S.M. Ilie, S. Ladoire. Annals of Oncology (2021)

- Efficacy of chemotherapy plus bevacizumab in recurrent multiforme glioblastoma: A real-life study. A.V.A Beige, S.M. Ilie. *Annals of Oncology* (2021)
- Is the Histopathological Subtype Important for Tumor Response to Irradiation in non-metastatic Esophageal Cancer?. Bacinschi XE, Ilie SM. *Rev. Chim.*, 71 (6), 2020, 205-211
- Pathologic Response After Weekly Paclitaxel versus Docetaxel in Operable Breast Cancer. Bacinschi XE, Ilie SM. *Cancer Manag Res.* 2020 Feb 26.
- Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes S.M. Ilie, S. Ladoire *Annals of Oncology* (2019)
- Rare Pelvic Malignant Tumors in Adults: Treatment Features and Clinical Outcome in Nonmetastatic Disease (Single Institution Experience). Bacinschi XE, Ilie SM. *Cancer Biother Radiopharm.* 2019 Feb;34(1):56-66. Bacinschi XE, Ilie SM.

Monographs (contributor)

- Reference Régional de Principes de prise en Charge de Cancer de Sein de Bourgogne-Franche-Comté et du Grand Est, <https://oncologik.fr/referentiels/dsrc/sein-principes-de-prise-en-charge>, 5 April 2024
- Référentiel régional de prise en charge de cancer de sein Bourgogne - Franche-Comté (ONCOBFC) et Grand Est (RRCGE), <http://oncologik.fr/referentiels/rrc/sein-principes-de-prise-en-charge>, 18 November 2019

Articles (coauthor) (last 5 years)

- Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib. Ladoire S, Kamga, A.M, Ilie S et al. *npj Breast Cancer* 11, 10 (2025).
- Real-world prevalence, treatment and survival of “high risk” early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry.Ladoire S, Ilie SM et al. *Breast.* 2024 Dec;78:103789.
- Effect of radiochemotherapy on peripheral immune response in glioblastoma. Hampe L, Ilie S, *Cancer Immunol Immunother.* 2024 May 16;73(7):133.
- Relationship between initial tumor burden and the probability of pathological complete response within molecular subtypes of early breast cancer treated with neoadjuvant chemotherapy Roussot N. Ilie S M et al. *Annals of Oncology* 35 (2024) S323 - S324
- Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy. Roussot N, Constantin G, Ilie SM et al. *Annals of Oncology* 34 (2023) S285.
- Are we using the right cut-offs to obtain maximum information from Ki-67 in patients with early breast cancer? Trifanescu OG, Bilteanu L, Ilie S et al. June 2023 *Journal of Clinical Oncology* 41(16_suppl):e12567-e12567
- Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer. Galland L, Roussot N, Desmoulins I, Ilie S et al. *Cancers (Basel).* 2023;15(4):1299.

- Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results. Réda M, Fouquier A, Desmoulins I, Ilie S et al. *Breast*. 2023;68:149-156.
- Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. Ballot E, Galland L, Mananet H, Ilie S et al. *Breast Cancer Res*. 2022;24(1):80. Published 2022 Nov 18.
- Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach. Reda M, Macaire P, Bellio H, Ilie S et al. *Cancer Chemother Pharmacol*. 2022;89(2):197-208.
- Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing. Galland L, Ballot E, Mananet H, Ilie S et al. *NPJ Breast Cancer*. 2022;8(1):28.
- Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study. Ladoire S, Goussot V, Redersdorff E, Ilie S et al. *Eur J Cancer*. 2021;148:359-370.
- Pharmacokinetics of Palbociclib in aReal-World Situation. Royer B, Kaderbhai C, Fumet JD, Ilie S et al. *Pharmaceuticals (Basel)*. 2021;14(3):181.
- Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients. *Pharmaceutics*. Marouille AL, Petit E, Kaderbhai C, Ilie S et al. 2021;13(10):1708. Published 2021 Oct 16.
- Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study. Heudel P, Delalogue S, Parent D, Ilie S et al. *Anticancer Res*. 2020;40(7):3905-3913.

Conferences, Meetings and Presentations

- Liquid Biopsy in Breast Cancer: friend or foe: CONFER 2024: 20-23 Novembre 2024, Iasi Romania
- Late rechallenge CDK 4/6 inhibitors in hormone receptors positive HER 2 negative CCB5 Seminar, ABC Congress, 8 November 2023, Lisbon, Portugal
- Immunogenic role of HERVs, human endogenous retroviruses, in breast cancer, Conférence Nationale d'Oncologie Gynécologique et Urologique, 7-9 Septembre 2023, Galati , Roumanie
- Prise en charge du cancer du sein « Hormonothérapie » Réunion Interrégionale Comité Scientifique 12 mai 2023, Strasbourg, France
- Triple negative breast cancer in the era of immunotherapy and CDK inhibitors, Summer School in Oncology Juin 2019, Bucharest, Romania
- Etio-pathogenic particularities of claudin-low ovarian cancer, National Conference of Gynaecologic Oncology, 12-14 September 2019, Galati, Romania

- Oncogenetic circuit in breast cancer: Regional Reunion Bourgogne Franche Comte October 2019, Dijon, France
- Non-metastatic Lobular Breast Cancer: general and therapeutical features: University Oncology Symposium, October 2018, Liege, Belgium
- Potential clinically useful prognostic biomarkers in early triple-negative breast cancer patients: Retrospective analysis and preliminary results, Romanian Society of Radiotherapy and Oncology Congress, 19–21 October 2017, Cluj-Napoca, Romania
- Systemic treatment options in pancreatic adenocarcinoma, Romanian Society of Radiotherapy and Oncology Congress, 3–6 November 2016, Bucharest, Romania
- What can we propose as adjuvant systemic treatment in early triple-negative breast cancer? Institute of Oncology Alexandru Trestioreanu Bucharest (single institution experience), Ilie S, Anghel R, Scientific Meeting of the Institute of Oncology Prof. Alexandru Trestioreanu, November 2015, Bucharest, Romania
- Systemic therapy in early triple-negative breast cancer, Ilie S, Anghel R, 14th National Conference of Medical Oncology, October 2015, Poiana Brasov, Romania

Fellowships/Awards

2016: 2nd Masterclass on Systematic Reviews in Cancer Care, Guidelines and Research, Belfast, United Kingdom, 10–14 June 2016
 2012: ESMO Research Clinical Fellowship
 2011: Fellowship Masterclass in Clinical Oncology Dubrovnik, Croatia
 2011: ESO Research Clinical Fellowship
 2008: Award for poster presentation, International Symposium on Supportive Care in Cancer Houston

Additional trainings

EORTC course, Clinical Trial Statistics for Non Statisticians, Brussels, Belgium, 12-15 June 2018

Cours Intensif de Cancérologie Digestive FFCD-PRODIGE, Nice, France 3-4 May 2018

16ème Cours Francophone supérieur sur les Cancers du sein & les Cancers gynécologiques, Nice, France, 10-12 January 2018

University Course in Biostatistics, Lille 2 University School of Medicine, Lille, France, October 2014 to June 2015

Formation à la méthodologie de la recherche clinique en Oncologie, Société Française du Cancer, Annecy, France, 11–13 Septembre 2014

Cours Supérieur Francophone sur le Cancer de Sein en situation métastatique, Nice, France, 15–17 January 2014

Signalisation cellulaire et cancer, Société Française du Cancer CME, Paris, 21–23 March 2013

EORTC Medical Oncology Course, Brussels, Belgium, October 2012 to March 2013

Le cours de chimiothérapie antitumorale et traitement médical du cancer, University Paris-Sud XI, Institute Gustave Roussy, Villejuif, France, 16–27 January 2012

University Course in Breast Pathology, University of Versailles Saint Quentin en Yvelines, Institute Curie, Saint Cloud, France, January–April 2014

University Course in Head and Neck Cancerology, University of Medicine Paris-Sud XI, Institute Gustave Roussy, Villejuif, France, October 2011 to June 2012

University Course in Clinical Cancerology, University of Medicine Paris-Sud XI, Institute Gustave Roussy, Villejuif, France, October 2011 to June 2012

Teaching Experience

University of Burgundy, Dijon France teaching and supervising senior residents in Medical Oncology and medical students from January 2019

Topics of formal courses

- Breast Cancer: principles of oncological treatment
- Brain metastasis: diagnostic and multimodal treatment
- Critical lecture of a scientific article in Oncology

University of Medicine and Pharmacy, Bucharest, Romania: teaching and supervising senior residents in Medical Oncology from December 2015 to February 2017

Topics of formal courses:

- Critical lecture of a scientific article in Oncology
- Basics of a general and systematic review
- Designing a research project
- Update on breast cancer management, early and locally advanced stages
- Update on upper gastrointestinal and colorectal cancer

University of Health, Lille 2, France: teaching and supervising junior oncology residents and medical students in Medical Oncology, December 2013 to December 2015

Topics of formal courses:

- Basics of prescribing a chemotherapy cycle
- Oncologic emergencies
- Breast cancer clinical management in early, locally advanced and metastatic stages
- Neuroendocrine bronchial and gastro-pancreatic tumours
- Oesophageal cancer, cancer of the pancreas
- Antiangiogenics in metastatic colorectal cancer
- HER2-positive gastric cancer

- Cancers of unknown primary site
- Management of brain metastases
- Management of complications of central venous catheters

Institute Jules Bordet, Brussels, Belgium: teaching and supervising senior residents in Medical Oncology from October 2012 to November 2013

Topics of formal courses:

- Assessment and management of malignant melanoma
- Endometrial cancer, epithelial and non-epithelial ovarian cancer
- Head and neck cancers
- Thyroid cancer

University of Pitesti, Faculty of Science, Romania: teaching basics in oncology for nurses, May 2007 to April 2010

Topics of formal courses:

- Classes of cytotoxic agents
- Management of chemotherapy extravasation
- Dyspnoea in advanced cancer patients
- Mucositis induced by chemotherapy and targeted agents

Language Skills

- Romanian: native
- English: fluent
- French: fluent

References

Professor Coutant C, Director of Georges Francois Leclerc Cancer Center, 1 Rue Professeur Marion, 21000 Dijon, France, Tel +33 380737501 CCoutant@cgl.fr

Professor François Ghiringhelli Director of UMR INSERM 1231, Head of TEAM 1, TIRECs: "Therapies and Immune REsponse in CancerS", Director of early clinical unit CLIP2, University of Burgundy, UFR Science de Santé. 7 boulevard Jeanne D'Arc 21000 Dijon , France, Tel : +33 3 80 73 75 00, fgiringhelli@cgl.fr, francois.ghiringhelli@u-bourgogne.fr

Professor Hebbar M, Department of Medical Oncology Department, University Hospital Huriez 1, rue Polonovski 59037, Lille, France, Tel: +33 32 044 546, mohamed.hebbar@chru-lille.fr

Professor Guigay J, Director of Cancer Center Antoine Lacassagne, 33 Avenue de Valombrose, 06100 Nice, France, Tel: +33 492 031 503, joel.guigay@nice.unicancer.fr

Professor Awada A, Head of Medical Oncology Clinic, Institute Jules Bordet, Boulevard de Waterloo 121, 1000 Brussels, Belgium, Tel: +32 25 413 189, ahmad.awada@bordet.be

Professor Anghel R, Head of Research Department, Institute of Oncology Alexandru Trestioreanu, Fundeni Street 252, 022328 Bucharest, Romania, Tel: +40 212 271 489, rodicamanghel@gmail.com